title: Vascular access malfunction: towards a more genecentric view.
abstract: A well-functioning vascular access is the cornerstone for an optimal hemodialysis treatment and an issue of major importance for the outcome of patients on chronic hemodialysis. Over the last few years reports supporting the aspect that mechanisms involved in vascular access malfunction are genetically controlled have been published. Triggered by two cases reported herein, we present a comprehensive review of the literature on an evolving field of particular significance to patients on hemodialysis.
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kirmizis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Chatzidimitriou
authors.forename: Fani
authors.initials: F
authors.lastname: Chatzopoulou
authors.forename: Georgios
authors.initials: G
authors.lastname: Tzimagiorgis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Malisiovas
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Papagianni
mesh_terms: D000368:Aged; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D005165:Factor V / Q000235:genetics; D051547:Heme Oxygenase-1 / Q000235:genetics; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D006435:Renal Dialysis / Q000009:adverse effects*; D053773:Transforming Growth Factor beta1 / Q000235:genetics
chemical_list: D053773:Transforming Growth Factor beta1; D016753:Interleukin-10; D005165:Factor V; D051547:Heme Oxygenase-1; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D007703:Peptidyl-Dipeptidase A